MOG and myeloid sarcoma: Eliseeva et al. and Peschl et al. reported that MOG, a significant biomarker associated with oligodendrocyte formation, may serve as a potential target for cellular and humoral immune responses in inflammatory demyelinating diseases, such as MS [94, 95].